GlassScriptPhysician profile
Robert P Loehr
NPI 1851351464
$2,612.09
in general payments reported to CMS, 2019-2025
13 companies · $1,464 in 2025
The $1,464 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $237 · 2024: $910 · 2025: $1,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,605 · Education: $6.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.29 |
| Education | $6.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $495.18 | 2024-2025 | Cobenfy |
| Abbvie INC. | $474.37 | 2023-2025 | |
| Alkermes, INC. | $441.68 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $413.81 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $241.98 | 2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.35 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $126.66 | 2024-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $106.23 | 2023-2025 | Spravato, Invega Trinza, Invega |
| Lilly USA, LLC | $44.23 | 2024 | Jardiance, Mounjaro |
| Neurocrine Biosciences, INC. | $43.14 | 2025 | |
| Noven Therapeutics, LLC | $36.22 | 2024 | Secuado, Xelstrym |
| Novo Nordisk INC | $13.41 | 2024 | Wegovy |
| Corium, LLC | $12.83 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Loehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.